Stock Analysis:Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Stock Target Raised
In a very recent research note sent to investors by Citigroup on Tuesday morning, Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) had its target price per share increased to $89.00. The firm now has a solid Sell rating on shares.
From a total of 10 analysts covering Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) stock, 0 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that NaN of the ratings are positive. The highest target price is $125 while the lowest target price is $79. The mean of all analyst targets is $113.9 with a 10.22% above today’s ($104.34) stock price. Ultragenyx Pharmaceutical Inc was the topic of 10 analyst reports since July 27, 2015 according to the firm StockzIntelligence Inc. Stifel Nicolaus initiated shares on December 1 with “Buy” rating. Raymond James initiated RARE stock in a recent report from September 1 with “Outperform” rating. Finally, SunTrust maintained the stock with “Buy” rating in a report issued on a July 13.
The stock increased 6.61% or $6.47 during the last trading session, striking $104.34. Approximately shares of stock traded hands. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) has risen 61.77% since May 6, 2015 and is uptrending. It has outperformed by 62.56% the S&P500.
The overall sentiment of institutions has increased to 2.25 in Q2 2015. Its up 0.44, from 1.81 in 2015Q2. The ratio increased, as 25 institutions have sold all the shares of Ultragenyx Pharmaceutical Inc that they owned while 27 funds have taken shares off the table. 31 funds have purchased shares for the first time while 86 added to their positions. These institutions now hold 32.84 million shares or 1.96% more than the 32.21 million shares they owned in 2015Q2.
The Fund Opaleye Management Inc. currently is holding shares equating to 5.21% of its total portfolio in Ultragenyx Pharmaceutical Inc representing a total of 110,000 shares. Another fund,Iguana Healthcare Management Llc, is holding a total of 110,000 shares equating to 4.17% of their holdings. Additionally, Weatherbie Capital Llc has a 206,880 share stake in Ultragenyx Pharmaceutical Inc which represents 2.31% of their total portfolio. The Fund, Cormorant Asset Management Llc, based out of Massachusetts, has also built up a stake in the stock, which represents a total of 1.68% of their total portfolio. Finally Columbia Wanger Asset Management Llc, a fund which is based in the state of Illinois reported a total holdings of 1.25 million shares.
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $3.80 billion. The Firm is focused on the identification, acquisition, development, and commercialization of products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. It currently has negative earnings. The Company’s pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies.
According to Zacks Investment Research, “Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company’s product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California.” Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical Inc (RARE).